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1. List publications: (a) published and not previously reported; (b) in press. Provide five reprints if not previously submitted. 
2. List all additions and deletions in professional personnel and any changes in effort. 
3. Progress Report. (Sea Instructions) 
la. Publications 
"Peptide Hydroxamic Acids as Inhibitors of Thermolysin," N. Nishino and J. C. 
Powers, Biochemistry, 17, 2846-2850 (1978). 
"Specificity and Reactivity of Human Granulocyte Elastase and Cathepsin G, 
Porcine Pancreatic Elastase, Bovine Chymotrypsin and Trypsin Toward Inhibition 
with Sulfonyl Fluorides," M. O. Lively and J. C. Powers, Biochem. Biophys. 
Acta, 525, 171-179 (1978). 
"Active Site Directed Irreversible Inhibition of Thermolysin," D. Rasnick 
and J. C. Powers, Biochemistry, 17, 4363-4369 (1968). 
"Synthetic Inhibitors of Elastase and Cathepsin G," James C. Powers, B. F. 
Gupton, M. O. Lively, N. Nishino and R. J. Whitley, Chap. in K. Havemann 
and A. Janoff (eds), "Neutral Proteases of Human Polymorphonuclear Leukocytes," 
"Urban and Schwarzenberg, Baltimore-Munich, pp 221-233, 1978. 
"Albumin Microsperes as Carrier of an Inhibitor of Leukocyte Elastase: Poten-
tial Therapeutic Agent for Emphysema," R. R. Martodalll, D. Y. Twumasi, I. E. 
Liner, J. C. Powers, N. Nishino and G. Krejcarek, Proc. Nat. Acad. Sci., 76, 
2128-2132 (1979). 
lb. "Virus-specified Protease in Poliovirus-infected Hela cells", B. Korant, N. 
Chow, M. Lively and J. Powers, Proc. Nat. Acad. Sci., 76, June 1979. 
"Inhibition of Thermolysin and Carboxypeptidase A by Phosphoramidates", C. 
Kam, N. Nishino, and J. C. Powers, Biochemistry, 18, July 1979. 
2. Dr. Norikazu Nishino returned to Japan to begin an academic career and 
is no longer working on the project. He will be replaced in June by Dr. 
Tadashi Teshima who received his Ph.D. degree in 1976 with Dr. Shiba at 
Osaka University. At present he has over 15 research publications in the 
area of peptide chemistry. 
3. Progress Report 
a. Overall Objectives for Total Project. A number of proteolytic enzymes 
such as elastase and collagenase have shown to be involved in diseases such 
as pulmonary emphysema and arthritis which involve tissue destruction. The 
goal of this proposed research is to design and synthesize specific and ef-
fective inhibitors for these proteolytic enzymes. The inhibitors should be 
invaluable in the study of the normal biological function and the role of these 
• 
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proteases in disease. In addition, synthetic protease inhibitors should find 
use in the clinical treatment of pulmonary emphysema, rheumatoid arthritis 
and other diseases. 
b. Goals for the Current Year. Our goals for the current year were to de-
velop new types of inhibitors for human leukocyte elastase (a serine pro-
tease) and to continue work on developing specific metalloprotease inhibi-
tors. 
c. Studies with Human Granulocyte Enzymes. Proteolysis by enzymes released 
from human PMN leukocytes, macrophages and other sources are involved in 
several major diseases which involve tissue destruction. In the case of pul-
monary emphysema, elastase seems to be principally responsible for lung 
damage with collagenase, cathepsin G and other proteases carring out secon-
ary digestions. We have previously synthesized a number of specific peptide 
chloromethyl ketone inhibitors of both human leukocyte elastase and cathepsin 
G. Two of the best elastase inhibitors, Meo-Suc-Ala-Ala-Pro-Va1CH2C1 and 
Ac-Ala-Ala-Pro-Va1CH2C1, have been shown to be effective at preventing emphy-
sema by two research groups (Dr. P. Stone, Boston University and Dr. J. 
Kleinerman, Mt. Sinai Medical Center). In both cases the hamster emphysema 
animal model was utilized. In addition, preliminary experiments indicate 
the inhibitors will reduce the severity of the disease if they are applied 
to animals after disease has been allowed to progress. Even though our pep-
tide chloromethyl ketones are effective, there has been considerable concern 
about their toxicity. Chloromethyl ketones are alkylating agents and would 
be expected to exhibit some carcinogencity. Thus most investigators believe 
that these compounds may not have utility for the treatment of human disease. 
Therefore we have begun a search for specific elastase inhibitors which have 
properties which would allow their utilization in humans. 
One type of compound which we are investigating are amino sulfonic acid 
derivatives. In particular we have synthesized sulfonyl fluorides such as 
1 and 2. The trifluoroacetyl derivative 2 was an extremely effective inhibi- 
so2., 
1 o, m, and 2. isomers 
tors of both human leukocyte elastase (kobsnI] = 500 M-1 s-l) and porcine 
pancreatic elastase (kobs/[I] = 2000 m -1 9-1). It was quite specific since 
the corresponding rates with human cathepsin G and bovine chymotrypsin were 
10 and 50 m-1 s-1 respectively. The acetyl compounds (1) were in contrast 
quite unreactive toward all the enzymes studied. Sulfonyl fluorides are not 
generally considered to be toxic and thus elastase inhibitors such as 2 may 
find utility in the treatment of human disease. 




might be possible to improve its reactivity and specificity. In addition, 
work will be directed toward the synthesis of Ac-Ala-Ala-NH-CH(R)S02F. Such 
peptide amino sulfonyl fluorides can be made to more closely imitate the 
structure of natural elastase substrates. Thus they may exhibit considerable 
specificity for elastase. 
d. Small Peptide Analogs of the a i -Protease Inhibitor. Another approach to 
elastase inhibitors is to make analogs of the a-protease inhibitor (al-anti-
trypsin) active site. The sequence at the active site has recently been de-
termined by Dr. J. Travis at the U. of GA. We were then able to design and 
synthesize small cyclic peptides such as 3 which have the a l -PI active site 
sequence. This peptide is a reversible inhibitor of human leukocyte elas- 
Ala-Leu-Pro-Met-Thr-Leu 
3 Abz = 3-aminobenzoyl 
tase (KI = 0.38 mM) and is not a substrate. Although 3 is only a moderate 
inhibitor, the peptide is a good lead compound for the development of new 
inhibitors. 
Our goals for the next year are to prepare analogs of 3 in order to 
improve binding to leukocyte elastase. Our first goal will be the synthe-
sis of an analogue of 3 where the Met-Thr unit is replaced by a Val-Ser 
unit. Leukocyte elastase prefers Val over Met at its primary substrate 
binding site and this change should increase the potency of the inhibitor. 
Cyclic peptide analogs of a l-PI are likely to be not toxic due to their 
close resemblance to the natural inhibitor. Synthetic elastase inhibitors 
seem to offer the best hope at present for the treatment of the majority of 
emphysema since natural a l-PI is difficult to isolate and purify. 
e. Studies with Metalloproteases. A number of metalloproteases are in-
volved in diseases which involve connective tissue destruction. Collage-
nase has been found in rheumatoid synovium and has been implicated in the 
destruction of joints in rheumatoid arthritis. Collagenase may also be 
involved in periodontal disease, corneal ulceration, and several other 
diseases. Invasive tumors have been shown to secrete collagenase and the 
ability of this enzyme to attack connective tissue may allow such tumors 
to expand into the surrounding tissue. 
Excellent progress has been made in the development of general classes 
of inhibitors for the metalloproteases family. Using thermolysin and car-
boxypeptidase as model systems in our initial experiments, we have investi-
gated phosphoramidates, hydroxamic acids, and thiols as competitive inhibi-




ramidates such as P-Leu-NH2 and P-Phe-O-K÷ are excellent inhibitors of 
thermolysin and carboxypeptidase A respectively. The hydroxamic acid NONH-
BMZ-Ala-Gly-NH2 (BZM=-COCH(CH 2C6H5)C0-) is a specific inhibitor of thermo-
lysin (KT  m  0.7 pM) and has been attached to agarose and used in the affin-
ity purification of thermolysin. A number of irreversible thermolysin in-
hibitors such as CICH2CON(OH)CH(CH2CH(CH3)2)CO2CH 3 have been designed and syn-
thesized. The site of reaction has been determined. Several hydroxamic acids 
thiols, and phosphoramidates with the appropriate sequence to inhibit collage-
nase have been synthesized. Some were observed to be moderate inhibitors. 
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Both will be tested as collaginase inhibitors. 
f. Pseudomonas aeruginosa Elastase. Pseudomonas aeruginosa elastase is an 
infectous organism which is resistant to many antibiotics. This organism 
causes hemorrhagic pneumonia in mink and corneal ulcers in man. The major 
cause of morbidy and mortality in cystic fibrosis is the severe, chronic 
persistent pulmonary infection with bacteria particularily P. aeruginosa. 
Many strains of P. aeruginosa produce an elastase. Those strains with 
elastase have been shown to be more pathogenic than those without. The 
Elastase is likely the factor responsible for the destruction of corneal 
tissue and hemorrhages of the lung observed in P. aeruginosa infections. 
P. aeruginosa is a zinc metalloprotease and we have developed a new 
substrate to assay the enzyme. Specific inhibitors for this elastase have 
been designed and synthesized. In particular, the hydroxamic acid HONH-
COCH2CH(CH2C6H5)CO-Ala-Gly-NH2 was a potent reversible inhibitor (ICI = 
0.044 pM) and C1CH2CO-H0 Leu-Ala-Gly-NH 2 was an irreversible inhibitor. 
Both compounds may find utility in the treatment of infections due to P. 
aeruginosa elastase. 
g. Significance. It is the belief of the author that reagents which con-
trol the activity of proteolytic enzymes can be used in a number of clini-
cally sitiations. Diseases involving tissue destruction such as emphysema 
and arthritis have been shown to involve enzymes such as elastase, cathepsin 
G and collagenase. Invasive tumors secrete collagenase possibility account-
ing for their ability to expand into the surrounding connective tissue. 
Viral protein processing requires a protease. Organisms like Neisseria  
Gonorrhoeae and N. meningitidis secrete proteases which cleave the principal 
mucosal antibody, immunoglobulin A. And P. aeruginosa produces an enzyme 




The basic goal of our research is to develop new classes of inhibitors 
for the two major families of proteases: serine and metalloproteases. 
Within this framework our emphasis have been directed toward inhibitors for 
granulocyte elastase and cathepsin G, and collagenase since these enzymes 
are involved in two major chronic diseases: emphysema and arthritis. In the 
course of this work we are learning new information about these specific en- 
zymes and about the two general classes of proteases. In addition we are 
discovering ways to increase the specificity of inhibitors both for a spe- 
cific enzyme within a class of proteases and for an enzyme when it is lo-
cated in its natural environment which may contain a multitude of other re-
active groups. The information should be useful to other investigators who 
desire specific inhibitors for other proteases. 
At present some of our elastase inhibitors are being tested in animals 
for the treatment of emphysema. There is a good possibility that the course 
of emphysema can be arrested by use of the appropriate inhibitor. At pres-
ent better elastase inhibitors are desired. Our studies with synthetic pro-
tease inhibitors are leading us closer to clinically useful drugs. 
The undersigned agrees to accept responsibility for the scientific technical 
conduct of the project and for provision of required progress reports if a grant 
is awarded as the result of this application. 
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g. Patient care costs 	• I. TOTAL 
2. Expenditures from Prior Periods (previously reported) 
3. CuMulative Expenditures 	 • 
236 658.91 
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242 621.00 ' 
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-0 
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2as_____ 
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